● Recruiting

Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML

Condition: Acute Myeloid Leukemia · Sponsor: The First Affiliated Hospital of Xiamen University

PhasePhase 2

Planned participants66

Who can joinAll sexes, 60 Years to no upper limit

Healthy volunteersNo

About this study

A multicenter, prospective, single-arm clinical study of veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) in the treatment of elderly untreated acute myeloid leukemia (AML)

This description comes directly from the study's public registry record.

Talk to the study team

Bing Xu · +8618750918842 · xubingzhangjian@126.com

Zhifeng Li · +8613606901162 · lzf_xm@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Bing Xu

Xiamen, Fujian, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06827899